|
|
Upfront Briefing
GSK went back to the Chimagen well for a myeloma trispecific worth up to $750M, while Novo handed Ascendis back the keys to a monthly GLP-1 it has now failed to land three different ways. One pharma reloading from China, one clearing out the last regime's bets. Curium got FDA to sign off Bexlutry, the first Lutathera equivalent: branded rather than generic, but Novartis will feel it all the same. FDA also opened TrialBlazer applications, the PDUFA VIII public meeting runs today, and Morgan Stanley's healthcare conference wraps in New York.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,585.7 |
(0.4%) |
10.8% |
| Nasdaq 100 |
28,937.8 |
(0.6%) |
14.8% |
| Russell 2000 |
2,870.3 |
(0.8%) |
15.6% |
| Healthcare (XLV) |
167.7 |
0.0% |
8.3% |
| Biotech (XBI) |
154.0 |
(2.3%) |
26.3% |
| Nasdaq Biotech (NBI) |
6,887.9 |
(1.5%) |
20.7% |
| Clinical Trials (BBC) |
48.5 |
(2.8%) |
29.0% |
|
- Biotech took the heavier hit: XBI (2.3%) and BBC (2.8%) against cap-weighted NBI (1.5%) and a flat XLV, so the damage sat in small- and mid-cap clinical names rather than large-cap pharma.
- The 10-year Treasury yield touched 5.04% early Tuesday, its highest since 2007, with Brent near $108 after Saudi Arabia shut its East-West pipeline and a 25bp Fed hike expected at today's decision.
- Market data: U.S. cash close Tuesday, 15 September 2026.
The Big 3
|
1
|
GSK goes back to Chimagen for a $750M myeloma trispecific
|
- GSK agreed to take full global rights to a preclinical trispecific T-cell engager from privately held Chimagen Biosciences for an undisclosed upfront plus development and commercial milestones, worth up to $750M in total. The molecule binds T cells and two unnamed tumour antigens; GSK expects Phase 1 in multiple myeloma in 2027, and the deal is subject to customary closing conditions.
- Why it matters: GSK paid Chimagen $300M upfront two years ago for the CD19xCD20 engager CMG1A46, so this is a repeat buyer paying for a platform it has already diligenced. The design case is tolerability. Tecvayli, Elrexfio, Lynozyfic and Talvey all carry boxed warnings for CRS and neurotoxicity and are approved only after four prior lines; an engager that hits two myeloma antigens with a cleaner safety profile could move up the treatment sequence. GSK is late to that idea. AbbVie paid Ichnos Glenmark $700M upfront for a CD38xBCMAxCD3 trispecific, and J&J has a BCMAxGPRC5DxCD3 trispecific in Phase 3. The upfront and targets are undisclosed, and China-sourced BD&L still carries COINS Act overhang. IMS Glasgow opens 23 September.
- Source: Fierce Biotech
- More: PharmExec
|
|
2
|
Novo walks away from its $285M monthly GLP-1 pact with Ascendis
|
- Novo terminated its November 2024 collaboration to develop a once-monthly GLP-1 receptor agonist on Ascendis' TransCon platform, a pact worth up to $285M in upfront, development and regulatory payments plus tiered royalties, with $77.5M in milestones attached to each additional programme. Ascendis disclosed the termination after Monday's close and will develop TransCon semaglutide, a monthly prodrug of Wegovy's active ingredient, on its own.
- Why it matters: Novo still does not own a monthly GLP-1, and this is the third route to one that has closed. It dropped a monthly GLP-1/GIP dual agonist in 2024, lost Metsera to Pfizer after last year's bidding war, and has now handed back the TransCon programme inside two years without a stated reason. The clean-out of Jørgensen-era bets is running fast under Doustdar: the CFO confirmed last month that nothing from the $1.1B Inversago buy will be pursued, and two more ziltivekimab Phase 3s were halted last week. Ascendis gets a semaglutide prodrug back for free but now funds obesity development alone, against Pfizer's Metsera assets and Amgen's MariTide. Doustdar said earlier this year Novo is still looking for a monthly asset.
- Source: Fierce Biotech
- More: BioPharma Dive
|
|
3
|
FDA clears Curium's Bexlutry, the first Lutathera equivalent
|
- FDA approved Curium's Bexlutry (lutetium Lu 177 dotatate) for adults with SSTR-positive gastroenteropancreatic neuroendocrine tumours through the 505(b)(2) pathway, referencing Novartis' Lutathera and supported by published evidence plus targeted bridging data. It is the first radioligand equivalent cleared in the U.S.; the paediatric indication stays with Lutathera under Novartis' marketing exclusivity.
- Why it matters: Bexlutry is a 505(b)(2) NDA, not an ANDA, so the right comp is branded competition rather than generic erosion. Curium sets its own price, carries its own name, and gives up the 12-and-over paediatric label to Novartis' exclusivity. The precedent is still the story. Lutathera has had SSTR-positive GEP-NETs to itself since 2018, and FDA has now accepted published evidence plus bridging data as enough to approve a lutetium copy that Curium says avoids the Orange Book patents. That shifts the defensible asset in radiopharma toward isotope supply: Curium pitches itself as the only vertically integrated lutetium NET manufacturer. Lu-177 capacity is already tight, and GE HealthCare's reported ~$1B move for Sofie points the same way.
- Source: Fierce Pharma
- More: PR
|
Everything Else that broke
- FDA opened applications for its Expedited IND pilot under Operation TrialBlazer, pairing sponsors with qualified research institutions for rolling pre-IND review; 8–10 pairs will be selected and the window closes 30 October. — BioPharma Dive
- FDA signaled tighter scrutiny of early-stage China data without imposing an outright ban. — BioCentury
- Sionna is cutting about 46% of staff, including its chief business officer, to take SION-451 plus SION-2222 into Phase 2a after last month's SION-719 cystic fibrosis miss; June cash of $268.3M now runs into 2H29. — Fierce Biotech
- Contineum's J&J-partnered JNJ-5120 missed the MADRS day-5 primary endpoint of the Phase 2 MOONLIGHT-1 study in major depression, and CTNM fell nearly 8% after hours. — Fierce Biotech
- Connect Biopharma's rademikibart cut 28-day treatment failure by about 66% in the 160-patient Seabreeze STAT Asthma Phase 2 but missed statistical significance on that primary endpoint; shares fell nearly 40% premarket. — Fierce Biotech
- Lilly signed a CNS genetic medicine collaboration with Canadian biotech QurCan Therapeutics worth up to $237M in milestones per programme. — Fierce Biotech
- Sanofi will move 20 older medicines to Cheplapharm in a mature-medicines partnership, with no impact on 2026 guidance and financial terms to follow. — Fierce Pharma
- FDA approved Telix's Pixclara, the first FET-PET imaging agent for glioma, more than a year after rejecting it. — Fierce Biotech
- BioMarin dropped Voxzogo development in Noonan syndrome as the treatment landscape shifts. — Fierce Pharma
- Japan approved Leqembi Pen as a subcutaneous option for early Alzheimer's disease. — PR
- Japan cleared Vyepti for adult migraine prevention, extending Lundbeck's CGRP footprint. — PR
- HHS deputy secretary nominee Chris Klomp sparred with Sen. Elizabeth Warren over undisclosed MFN deal contracts at his Senate Finance Committee confirmation hearing. — Endpoints
- FDA holds its PDUFA VIII public meeting today, with rare-disease reform, CMC risk and reshoring U.S. trials at the top of stakeholder agendas. — BioSpace
- Legend named former Novartis commercial leader Ingrid Zhang as CEO. — BioCentury
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- GSK / Chimagen Biosciences — full global rights to a preclinical myeloma trispecific T-cell engager; undisclosed upfront, up to $750M total, Phase 1 in 2027. — Fierce Biotech
- Novo / Ascendis — Novo terminated the November 2024 TransCon monthly GLP-1 collaboration (up to $285M); rights revert to Ascendis. — Fierce Biotech
- Lilly / QurCan Therapeutics — CNS genetic medicine collaboration, up to $237M in milestones per programme. — Fierce Biotech
- Sanofi / Cheplapharm — 20 mature medicines moved into a strategic partnership; financial terms to follow. — Fierce Pharma
- Jaguar / J&J — newly formed Jaguar acquired AFib device assets from J&J. — Fierce Biotech
- VaxThera / Codagenix — partnership on Syn17D-YF, a next-generation yellow fever vaccine candidate. — PR
VC / Private Financings
- Aitiologic raised €6.4M in an oversubscribed seed co-led by Heal Capital and Ananda Impact Ventures, for a tissue-resolved liquid biopsy platform led by a preeclampsia programme. — BioSpace
IPOs / Follow-Ons
- No notable IPOs / follow-ons in the last 24 hours.
Academic Corner - China's Decree 818 will hinge on consistent enforcement and adverse-event reporting to keep biomedical translation safe and accountable. — Nature Biotech
|
That's the open. The Fed speaks at 2pm ET, and your XBI screen will have opinions. — BioBucks Team
|
|
|
